Letters sent to healthcare professionals in November 2017

Letters were sent about eluxadoline (Truberzi), fingolimod (Gilenya), Bleo-Kyowa (bleomycin sulphate), Buccolam (midazolam), and ERWINASE.

From:
Medicines and Healthcare products Regulatory Agency
Published
14 December 2017
Therapeutic area:
Cancer, Dentistry, GI, hepatology and pancreatic disorders, Haematology and oncology and Neurology

In November 2017, the following letters were sent to relevant healthcare professionals to inform them of updated safety information:

  • Eluxadoline (Truberzi 鈻�):

  • Fingolimod (Gilenya鈻�):

  • Bleo-Kyowa (bleomycin sulphate), powder for solution for injection 鈥� 鈥� see Caution in Use alert

  • Buccolam (midazolam) prefilled plastic syringes: 鈥� see Caution in Use alert

  • ERWINASE: notice of special handling instructions鈥�

Article citation: Drug Safety Update volume 11, issue 5; December 2017: 7.

Updates to this page

Published 14 December 2017